<DOC>
	<DOCNO>NCT02161159</DOCNO>
	<brief_summary>This study evaluate real world pattern use BOTOX® actual clinical practice patient idiopathic overactive bladder ( iOAB ) urinary incontinence whose symptom adequately manage oral anticholinergic therapy .</brief_summary>
	<brief_title>An Observational Study BOTOX® Management Urinary Incontinence Patients With Idiopathic Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>No prior treatment botulinum toxin Type A treatment iOAB Treatment botulinum toxin Type A within 18 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>